Neuroblastoma is a childhood cancer that typically affects children under the age of five, with a median age of diagnosis between one and two. It accounts for 15% of all childhood cancer deaths. For high-risk patients, the highly toxic treatment and the young age of the patients give rise to devastating developmental defects and other side effects. Our studies are aimed to improve diagnosis, lead to development of new therapies, and better animal models for testing new therapeutics.

Project members

Lead investigator

Researchers

Professor Ernst Wolvetang

Senior Group Leader
Wolvetang Group
UQ-StemCARE Director